Top 10 for 2021: #9 | PARP Inhibitors for Prostate Cancer
With a one-in-nine chance of diagnosis, the disease is an ever-present worry for men. Researchers are constantly looking for new options for prostate cancer resistant to therapies, including metastatic castrate-resistant prostate cancer, or MCRPC, which is considered incurable.
Known for their success in women's cancers, poly ADP-ribose polymerase, or PARP inhibitors, have recently shown success as a targeted cancer therapy in men with similar BRCA gene mutations. While chemotherapy damages DNA as a way to hurt and kill rapidly dividing cancer cells, BRCA genes have a built-in backup plan to repair cancer DNA. PARP proteins fix this damage, allowing the cancer to grow. The inhibitor of PARP prevents repair, effectively blocking cell growth.